AJCN EB Program 2010 Early Registration
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Aamodt, R. L.
Right arrow Articles by Henkin, R. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aamodt, R. L.
Right arrow Articles by Henkin, R. I.
Agricola
Right arrow Articles by Aamodt, R. L.
Right arrow Articles by Henkin, R. I.

American Journal of Clinical Nutrition, Vol 32, 559-569, Copyright © 1979 by The American Society for Clinical Nutrition, Inc


ORIGINAL RESEARCH COMMUNICATIONS

Zinc metabolism in humans after oral and intravenous administration of Zn-69m

RL Aamodt, WF Rumble, GS Johnston, D Foster and RI Henkin

Seventeen patients were studied after separate oral and intravenous administration of 50 muCi Zn-69m to determine if Zn-69m is suitable for studying zinc metabolism in humans and to determine if the route of administration affects kinetics. Patients stayed on a metabolic ward for each study. Activity was measured in the total body, urine, feces, blood, plasma, red blood cells, and by detectors over liver and thigh. Five day urine to fecal ratios were 0.44 (intravenous), 0.018 (oral). Most activity went rapidly to liver, then followed two component exponential loss patterns in both cases. Thigh area doubling time was 5.7 days whether the zinc was given orally or intravenously. Plasma activity decreased to less than 2% of that injected by 24 hr after intravenous administration and decreased from a maximum of 1.2% of that ingested, 3 hr after oral administration to 0.7% by 24 hr. Red blood cell activity increased through the 5-day study period to maximum values of 6.4% of that injected after intravenous administration and 2.4% of that ingested after oral administration. Similar metabolic patterns were observed regardless of whether Zn-69m was administered intravenously or orally, suggesting that these patterns were not affected by the mode of administration for the cases studied.


This article has been cited by other articles:


Home page
BiostatisticsHome page
R. T. Ogden and T. Tarpey
Estimation in regression models with externally estimated parameters
Biostat., January 1, 2006; 7(1): 115 - 129.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Coll. Nutr.Home page
S.K. Dutta, F. Procaccino, and R. Aamodt
Zinc Metabolism in Patients with Exocrine Pancreatic Insufficiency
J. Am. Coll. Nutr., December 1, 1998; 17(6): 556 - 563.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1979 by The American Society for Nutrition